Antiretroviral drugs are now available in developing countries at a moderate cost. People living with HIV can live almost normal lives if provided with and adhering to treatment. HIV has shifted from a medical issue to a financial issue: in poor and high-prevalence countries, commitments to increase access to antiretroviral treatment create a huge fiscal liability. In this research, I study how domestic and international financing can be used to meet this liability.